Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026)
Immunome (IMNM) posted Depreciation & Amortization (CF) of $603000.0 for Q1 2026, down 9.05% on a QoQ basis from $663000.0 in Q4 2025, and down 1.31% year-over-year from $611000.0 in Q1 2025.
Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Immunome's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $603000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 1.31% year-over-year to $603000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 21.32% YoY) and the FY2025 annual result came in at $2.5 million, up 56.25% from the prior year.
- Depreciation & Amortization (CF) was $603000.0 for Q1 2026 at Immunome, down from $663000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $663000.0 in Q4 2025 and bottomed at $73000.0 in Q4 2022.
- A 5-year average of $329588.2 and a median of $194000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 63.99% — and 2024, when it soared 443.56%.
- Immunome's Depreciation & Amortization (CF) stood at $73000.0 in 2022, then jumped by 165.75% to $194000.0 in 2023, then soared by 148.97% to $483000.0 in 2024, then jumped by 37.27% to $663000.0 in 2025, then decreased by 9.05% to $603000.0 in 2026.
- Business Quant data shows IMNM's Depreciation & Amortization (CF) at $603000.0 in Q1 2026, $663000.0 in Q4 2025, and $589000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Immunome | 2.51 Bn | 1.93 Bn | - | 603,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 603,000.00 |
| Mar 31, 2026 | 603,000.00 |
| Dec 31, 2025 | 663,000.00 |
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Mar 31, 2025 | 611,000.00 |
| Mar 31, 2025 | 611,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Sep 30, 2024 | 411,000.00 |
| Sep 30, 2024 | 411,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 194,000.00 |
| Dec 31, 2023 | 194,000.00 |